| Trial ID: | L2805 |
| Source ID: | NCT00238472
|
| Associated Drug: |
Nateglinide
|
| Title: |
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: nateglinide
|
| Outcome Measures: |
Primary: Change from baseline in postprandial glomerular filtration rate at 12 weeks | Secondary: Change from baseline in fasting morning glomerular filtration rate at 12 weeks|Change from baseline in postprandial renal plasma flow at 12 weeks|Change from baseline in fasting morning renal plasma flow at 12 weeks|Change from baseline in adjusted 2-hour postprandial glucose at 12 weeks|Change in insulin AUC (0-240 minutes) at 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-05
|
| Completion Date: |
2005-06
|
| Results First Posted: |
|
| Last Update Posted: |
2012-04-27
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00238472
|
